Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 1/20 | 0.61 |
| ▸ | MAOB | P27338 | 5/20 | 0.51 |
| ▸ | KDM1A | O60341 | 4/20 | 0.51 |
| ▸ | MAOA | P21397 | 3/20 | 0.51 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.45 |
| ▸ | DRD2 | P14416 | 1/20 | 0.43 |
| ▸ | DRD4 | P21917 | 1/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.42 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18906092 | 0.94 | HTR2C (0.55) | HTR2CMAOBKDM1AMAOATAAR1 | |
| SCHEMBL6250305 | 0.81 | HTR2C (0.63) | HTR2CMAOBKDM1AMAOADRD2 | |
| SCHEMBL6056591 | 0.80 | HTR2C (0.61) | HTR2CMAOBKDM1AMAOADRD2 | |
| SCHEMBL23995535 | 0.79 | HTR2C (0.69) | HTR2CMAOBKDM1AMAOADRD2 | |
| SCHEMBL16591278 | 0.79 | HTR2C (0.69) | HTR2CMAOBKDM1AMAOADRD2 | |
| SCHEMBL6056599 | 0.79 | HTR2C (0.59) | HTR2CMAOBKDM1AMAOADRD2 | |
| SCHEMBL17346800 | 0.77 | ESR1 (0.46) | HTR2CMAOBKDM1ATAAR1SIGMAR1 | |
| SCHEMBL17985307 | 0.77 | HTR2C (0.67) | HTR2CMAOBKDM1AMAOADRD2 | |
| SCHEMBL16585494 | 0.77 | HTR2C (0.67) | HTR2CMAOBKDM1AMAOADRD2 | |
| SCHEMBL24529204 | 0.77 | HTR2C (0.67) | HTR2CMAOBKDM1AMAOADRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9994518-B2 | Alpha-7 nicotinic acetylcholine receptor modulators and uses thereof | MERCK SHARP & DOHME CORP. (US) | 2018-06-12 | — | — | US | disclosed |
| US-20170152221-A1 | ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS AND USES THEREOF | MERCK SHARP & DOHME CORP. (US) | 2017-06-01 | — | — | US | disclosed |
| WO-2015191799-A1 | ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS AND USES THEREOF | MERCK SHARP & DOHME CORP. (US) | 2015-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170152221-A1 | ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS AND USES THEREOF | CHRNA7, CHRNA10, CHRNA5 | HTR2C 455/4885MAOB 332/4885KDM1A 2503/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.